Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Dongzhimen Hospital, Beijing
Modality
UNKNOWN
Development Phase
N/A
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05169450CT.gov Efficacy of Diterpene Ginkgolides Meglumine Injection in Elderly Patients With Ischemic Stroke | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cerebral Infarction
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Diterpene Ginkgolides Meglumine (this asset) | Dongzhimen Hospital, Beijing | N/A | D · 30 |
| Cilostazol | Asan Medical Center | P4 | BBB |
| Aspirin | Sclnow Biotechnology Co., Ltd. | P4 | BBB |
| Sovateltide | Pharmazz, Inc. | P4 | BBB |
| Clopidogrel | The Second Hospital of Anhui Medical University | P4 | BBB |
| Human Urinary Kallidinogenase | Huisheng Chen | P4 | BB |
| Tenecteplase | Second Affiliated Hospital, School of Medicine, Zhejiang University | P3 | BB |
| Erigeron | Guangzhou University of Traditional Chinese Medicine | P4 | BB |
| Atorvastatin | Sclnow Biotechnology Co., Ltd. | P4 | BB |
+41 more in the Cerebral Infarction cohort
Other indications for Diterpene Ginkgolides Meglumine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Nervous System Disorder | — | N/A | D · 30 |
| Brain Ischemia | — | N/A | D · 30 |
| Brain Infarction | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Diterpene Ginkgolides Meglumine in Cerebral Infarction. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/diterpene-ginkgolides-meglumine-cerebral-infarction
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →